Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

JAMA oncology - 1 May 2018

Mascarenhas John, Hoffman Ronald, Talpaz Moshe, Gerds Aaron T, Stein Brady, Gupta Vikas, Szoke Anita, Drummond Mark, Pristupa Alexander, Granston Tanya, Daly Robert, Al-Fayoumi Suliman, Callahan Jennifer A, Singer Jack W, Gotlib Jason, Jamieson Catriona, Harrison Claire, Mesa Ruben, Verstovsek Srdan

Abstract excerpt

Importance: Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. Objective: To compare the efficacy and safety of JAK2 inhibitor pacritinib with that of best available therapy (BAT), including ruxolitinib, in patients with myelofibrosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged-Ring Compounds
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 29522138
DOI: 10.1001/jamaoncol.2017.5818
PMCID: PMC5885169

Genes

JAK2
JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.PMID 29522138Read ↗

Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.Semantic proximity Read ↗

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Semantic proximity Read ↗

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.Semantic proximity Read ↗

Comparison of Momelotinib, Pacitinib and Ruxolitinib in patients with Myeloproliferative Neoplasm: An Indirect-Comparison Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.